Thus, the positive correlation of CASC19 and PSPC1 expression and the CASC19/PSPC1/β-catenin axis seems to be a promising therapeutic target in pancreatic cancer treatment. This evidence concerns the gene PSPC1 and familial pancreatic carcinoma.